Functional Endoscopic Dilatation of the Paranasal Sinuses
All around the Nose: Basic Science, Diseases and Surgical Management, Springer International Publishing Ag, ss.605-610, 2019
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2019
- Doi Numarası: 10.1007/978-3-030-21217-9_67
- Yayınevi: Springer International Publishing Ag
- Sayfa Sayıları: ss.605-610
- Anahtar Kelimeler: Adhesions, Balloon catheterization, Balloon sinuplasty, Chronic rhinosinusitis, Minimizing postoperative scar formation, Narrowed sinus ostium
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
As we acquire a better understanding of the pathophysiology of chronic rhinosinusitis (CRS), the requisite for less invasive, mucosal sparing, “functional” surgical approaches has emerged. Recent technologic advances including balloon sinus ostial dilation have provided minimally invasive treatment options for this common disease entity which have optimized tissue preservation. The concept of balloon catheterization has long been applied in urology, cardiology, and gastroenterology. Balloon sinuplasty was adopted from angioplasty to dilate the ostia of the paranasal sinuses by Californian engineers in 2002. This catheter-based technology was first demonstrated at the annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery in Los Angeles, California, USA, in 2005; and the first publications on the safety and feasibility of this technique appeared in the global literature the following year. Balloon sinuplasty aims to preserve both the function and mucosa of the sinuses through gentle restructuring of the narrowed sinus ostium. Balloon dilatation results in microfractures and bony displacement, causing widening of the natural ostium and subsequent ventilation of the sinus drainage pathways. Tissue resection is averted, thus minimizing postoperative scar formation and adhesions. This procedure is primarily used to treat CRS involving the frontal, sphenoid, or maxillary sinuses without nasal polyposis, with sustained positive clinical outcomes for at least 2 years.